An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Management of Relapsed and Relapsed/Refractory Multiple Myeloma

(2017) Jacob P. Laubach et al.   Journal of the National Comprehensive Cancer Network

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Novel Proteasome Inhibitors to Overcome Bortezomib Resistance

(2011) Amy M. Ruschak et al.   JNCI-Journal of the National Cancer Institute

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

(2010) G. Dasmahapatra et al.   BLOOD

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

(2010) Donna E. Reece et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

(2010) B. Mohty et al.   HAEMATOLOGICA

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

Multiple Myeloma

(2009) S. Vincent Rajkumar   CURRENT PROBLEMS IN CANCER

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

(2009) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

The proteasomal system

(2009) Tobias Jung et al.   MOLECULAR ASPECTS OF MEDICINE

Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer

(2008) Bruce D. Dorsey et al.   JOURNAL OF MEDICINAL CHEMISTRY